Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

RATIONALE Incident pulmonary arterial hypertension was underrepresented in most pulmonary hypertension registries and may have a different disease profile to prevalent disease. OBJECTIVES To determine the characteristics and outcome of a purely incident, treatment-naive cohort of idiopathic, heritable, and anorexigen-associated pulmonary arterial hypertension and to determine the changes in presentations and survival over the past decade in the United Kingdom and Ireland. METHODS All consecutive newly diagnosed patients from 2001 to 2009 were identified prospectively. MEASUREMENTS AND MAIN RESULTS A total of 482 patients (93% idiopathic, 5% heritable, and 2% anorexigen-associated pulmonary arterial hypertension) were diagnosed, giving rise to an estimated incidence of 1.1 cases per million per year and prevalence of 6.6 cases per million in 2009. Younger patients (age ≤ 50 yrs) had shorter duration of symptoms, fewer comorbidities, better functional and exercise capacity, higher percent diffusing capacity of carbon monoxide, more severe hemodynamic impairment, but better survival compared with older patients. In comparison with the earlier cohorts, patients diagnosed in 2007-2009 were older, more obese, had lower percent diffusing capacity of carbon monoxide,(,) and more comorbidities, but better survival. Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) equation, REVEAL risk score, and Pulmonary Hypertension Connection Registry survival equation accurately predicted survival of our incident cohort at 1 year. CONCLUSIONS This study highlights the influence of age on phenotypes of incident pulmonary arterial hypertension and has shown the changes in demographics and epidemiology over the past decade in a national setting. The results suggest that there may be two subtypes of patients: the younger subtype with more severe hemodynamic impairment but better survival, compared with the older subtype who has more comorbidities.

[1]  R. Benza,et al.  The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. , 2012, Chest.

[2]  P. Corris,et al.  S71 Influence of age on clinical phenotypes of incident idiopathic pulmonary arterial hypertension. Results from the pulmonary hypertension registry of the UK and Ireland , 2011, Thorax.

[3]  J. Lordan,et al.  S72 Prediction of survival in pulmonary arterial hypertension using survival equations. Results from the pulmonary hypertension registry of the UK and Ireland , 2011, Thorax.

[4]  J. Lordan,et al.  Late-breaking abstract: Demographic trends and changes In long term outcome of incident idiopathic, heritable and anorexigen-associated pulmonary arterial hypertension between 2001 to 2009. Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland , 2011 .

[5]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[6]  M. Humbert,et al.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[7]  M. Humbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[8]  I. Schulze-Neick,et al.  Childhood idiopathic pulmonary arterial hypertension: a national cohort study , 2010, Heart.

[9]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[10]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[11]  Sanjiv J. Shah,et al.  Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation , 2009, European Respiratory Journal.

[12]  G. Filippatos,et al.  Guidelines for the diagnosis and treatment of pulmonary hypertension , 2009 .

[13]  S. Halpern,et al.  Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. , 2009, Chest.

[14]  Tianxi Cai,et al.  The Performance of Risk Prediction Models , 2008, Biometrical journal. Biometrische Zeitschrift.

[15]  M. Zwahlen,et al.  Epidemiology of pulmonary hypertension: new data from the Swiss registry. , 2008, Swiss medical weekly.

[16]  G. MacGowan,et al.  Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland , 2008, Heart.

[17]  M. Humbert,et al.  Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases , 2008, European Respiratory Journal.

[18]  S. Rich,et al.  A USA-based registry for pulmonary arterial hypertension: 1982–2006 , 2007, European Respiratory Journal.

[19]  Z. Jing,et al.  Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. , 2007, Chest.

[20]  J. McMurray,et al.  An epidemiological study of pulmonary arterial hypertension , 2007, European Respiratory Journal.

[21]  M. Mcgoon,et al.  Unexplained pulmonary hypertension in elderly patients. , 2007, Chest.

[22]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[23]  R. Speich,et al.  Severe pulmonary hypertension: data from the Swiss Registry. , 2001, Swiss medical weekly.

[24]  M. Yigla,et al.  Primary pulmonary hypertension in Israel: a national survey. , 2001, Chest.

[25]  P. Enright,et al.  Predictors of longitudinal change in diffusing capacity over 8 years. , 1999, American journal of respiratory and critical care medicine.

[26]  J. Hankinson,et al.  American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update. , 1995, American journal of respiratory and critical care medicine.

[27]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[28]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[29]  G. Brier.  VERIFICATION OF FORECASTS EXPRESSED IN TERMS OF PROBABILITY , 1950 .